TALENs (TAL effector nucleases) and CRISPR/Cas9 systems use engineered nucleases that promote double stranded breaks in the genome, stimulating gene targeting by activating cellular repair pathways. With targeting efficiencies as high as 75%, TALENs and CRISPR/Cas9 not only outperform traditional genome engineering methods but also drastically reduce the cost and timeframe associated with generating targeted mutations. In addition to gene targeting in mice, TALENs and CRISPR/Cas9 can target organisms and cell types previously not amenable to such approaches including zebrafish, rats, drosophila, and C. elegans as well as human stem cells and iPSCs (induced pluripotent stem cells). Attesting to its usefulness, genome editing with engineered nucleases was named “Nature Method of the Year” in 2011.
The Transgenic Vectors Core designs and constructs TALENs and CRISPR/Cas9 vectors for genome engineering. Services are offered in a tiered fashion such that investigators can choose those services they specifically need. Microinjection, genotyping services are offered through the Mouse Genetics Core, Zebrafish Facility.
The Transgenic Vector Core’s effort on TALENs and CRISPR/Cas9 is supported by the McDonnell Center for Cellular and Molecular Neurobiology.
- Target Site Sequence Verification: $250
- Design and Construction of TALENs pair: $750
- Design and Construction of CRISPR/Cas9: $500
- Validation of TALENs or CRISPR/Cas9 activity: $250
- TALENs or CRISPR/Cas9 RNA prep: $250
For inquiries, contact Transgenic Vectors Core Director Renate Lewis.